Alkemi

Transformative cell and gene therapies are revolutionizing medicine, but complex access barriers stand in their way. At Alkemi, we've pioneered strategies that have helped successfully launch 18 breakthrough treatments since 2019. At Advanced Therapies USA 2024 we explored the core challenges: evidence requirements, pricing models, and market access pathways. Ready to collaborate? Let's ensure your innovative therapy reaches the patients who depend on it. #CellandGene #MarketAccess #HEOR #AdvancedTherapiesUSA2024 #RareDisease #Breakthrough

The market access playbook is obsolete. The symptoms? FDA panels vote 13-1 against efficacy, but drug stay on market. Proven obesity treatments get denied as "cosmetic." Why healthcare's next Breakthrough won't come from following the rules. #atlasshrugged #marketaccess #pharma #heor #rwe https://lnkd.in/gYh3EgCB

Counting down to #ISPOREurope2024! I’ll be sharing our research on capturing the unique journeys of individuals living with rare diseases. At Alkemi, we know that Breakthrough treatments are most impactful when we understand patient needs and access barriers. Join me in exploring how we can do more for rare disease communities. Would love to?connect?in Barcelona! #MarketAccess #HEOR #Consulting #RareDisease

Our #ISPOREurope2024 poster provides an in-depth look at real-world patient journey research methods. For those working on Breakthrough treatments, understanding these journeys is essential to creating market access strategies that truly make an impact. We know this because we helped launch 18 Breakthrough treatments in the last 5 years. Let's discuss your Breakthrough: Visit our ISPOR poster (MSR19) on Monday, November 18, 10:30 - 13:30 Grab a coffee with Kristen Cribbs at ISPOR: https://lnkd.in/ew_4rSWH #MarketAccess #HEOR #Consulting #RareDisease #Alkemi #breakthrough #acceleratedapproval

?????????? ???? ?????????? ???? ????:???? for a 15-minute Primer on Price Transparency: ?What it is ?Why it matters ?How industry can engage Date: ?????????? Wednesday, November 6 Time: 12:15 – 12:30 PM Location: MS Teams https://lnkd.in/gzTDcbmE Late arrivals are welcome to join anytime during the session. Attendee privacy is assured as only Alkemi will have access to participant names. Participant microphone and cameras will be disabled. #RareDisease #Pricetransparency #marketaccess #heor

Breakthrough treatments require breakthrough strategies. Join Lake Murphy, Alkemi Market Access Manager, as he moderates a distinguished panel of industry and policy experts on "Improving Patient Access: Alternative Pricing Models and Outcomes-Based Agreements." Discover insights into the unique challenges of launching breakthrough treatments and strategies to overcome them. Don’t miss this opportunity to learn more about advancing patient access at Advanced Therapies USA 2024. ?? Panelists: Erica Cischke, Andrew York, Ellen Lukens & Kelly Kilpatrick #MarketAccess #HEOR #Consulting #Cell #Gene #AdvancedTherapiesUSA2024.

Ready to talk evidence, pricing, access, and cheesesteaks? Alkemi is excited to attend Advanced Therapies USA 2024 in #Philadelphia, the City of Brotherly Love! We look forward to connecting with you there and settling the debate: Who's the best? Pat's King of Steaks OR Geno’s Steaks #marketaccess #value #evidence #cell #gene #therapy #adtherapiesUSA #advancedtherapies

?? Attention Rare Disease Executives?? Join Alkemi for a 15-minute overview to discover how the new FDA Rare Disease Innovation Hub initiative could impact your strategy and open new doors for collaboration and growth. Date: Tuesday, September 17 Time: 12:15 – 12:30 PM Location: MS Teams https://lnkd.in/ewVEcphe Can't make it? Download our white paper - https://lnkd.in/e7dA5t4Q Late arrivals are welcome to join anytime during the session. Attendee privacy is assured as only Alkemi will have access to participant names. #RareDisease #Innovation #FDA #Alkemi #HealthcareLeadership #thehub

Alkemi is excited to welcome Ethan Donnelly to our team as an Associate Consultant! Ethan brings expertise in research, analysis, and commercialization strategy. With a biomedical engineering degree from Tufts University, Ethan has led high-impact projects, including developing a U.S. orphan drug database and conducting market access assessments for rare disease assets. Ethan's experience spans U.S. and international markets. As healthcare budget pressures grow, the demand for actionable, commercially effective market-shaping strategies increases. Alkemi is committed to meet the needs of our expanding client base. Join us in welcoming Ethan to the Alkemi team! ?? #raredisease #marketaccess #value #access #evidence #marketshaping #consulting #biomedicalengineering #healthcarestrategy #lifeSciences #commercialization #rwe

?? Discover the leading trends shaping health system pharmacies by joining our pharmacists' insights session. ? 15 Minute Lunch Fast Facts Session: Ensuring Your Assets are Future-Ready Date: Wednesday, August 28 Time: 12:15 – 12:30 PM Location: MS Teams https://lnkd.in/eTGkWCqd Late arrivals are welcome to join anytime during the session. Attendee privacy is assured as only Alkemi will have access to participant names. #healthsystem #pharmacy #raredisease #marketaccess #marketshaping #consulting